Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway.
dc.contributor.author | Botteri, Edoardo | |
dc.contributor.author | Støer, Nathalie Charlotte | |
dc.contributor.author | Sakshaug, Solveig | |
dc.contributor.author | Graff-Iversen, Sidsel | |
dc.contributor.author | Vangen, Siri | |
dc.contributor.author | Hofvind, Solveig | |
dc.contributor.author | de Lange, Thomas | |
dc.contributor.author | Bagnardi, Vincenzo | |
dc.contributor.author | Ursin, Giske | |
dc.contributor.author | Weiderpass, Elisabete | |
dc.date.accessioned | 2018-02-16T11:24:42Z | |
dc.date.accessioned | 2018-06-22T06:47:22Z | |
dc.date.available | 2018-02-16T11:24:42Z | |
dc.date.available | 2018-06-22T06:47:22Z | |
dc.date.issued | 2017-11-15 | |
dc.identifier.citation | Botteri E, Støer N, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, de Lange T, Bagnardi, Ursin G, Weiderpass E. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway.. BMJ Open. 2017;7(11) | en |
dc.identifier.issn | 2044-6055 | |
dc.identifier.issn | 2044-6055 | |
dc.identifier.uri | https://hdl.handle.net/10642/5980 | |
dc.description.abstract | Objectives: With the present study, we aimed to investigate the association between menopausal hormone therapy (HT) and risk of colorectal cancer (CRC). Setting: Cohort study based on the linkage of Norwegian population-based registries. Participants: We selected 466822 Norwegian women, aged 55–79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user. Outcome measures: The outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence. Results: During the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen–progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively. Conclusions: In our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC. | en |
dc.language.iso | en | en |
dc.publisher | BMJ Publishing Group | en |
dc.relation.ispartofseries | BMJ Open;Volume 7, Issue 11 | |
dc.relation.uri | http://bmjopen.bmj.com/content/bmjopen/7/11/e017639.full.pdf | |
dc.rights | Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/ © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Menopausal hormone therapies | en |
dc.subject | Colorectal cancer | en |
dc.subject | Nationwide registries | en |
dc.subject | Norway | en |
dc.title | Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway. | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2018-02-16T11:24:42Z | |
dc.description.version | publishedVersion | en |
dc.identifier.doi | http://dx.doi.org/10.1136/bmjopen-2017-017639 | |
dc.identifier.cristin | 1560485 | |
dc.source.journal | BMJ Open |
Files in this item
This item appears in the following Collection(s)
-
HV - Institutt for naturvitenskapelige helsefag [441]
HV - Department of Life Sciences and Health
Except where otherwise noted, this item's license is described as Open Access: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/ © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.